Identification of four novel loci associated with psychotropic drug-induced weight gain in a Swiss psychiatric longitudinal study: A GWAS analysis.
Jennifer SjaardaAurélie DelacrétazCéline DubathNermine LaaboubMarianna PirasClaire GrosuFrederik VandenbergheSéverine CrettolNicolas AnsermotFranziska GammaKerstin Jessica PlessenArmin von GuntenPhilippe ConusZoltán KutalikChin-Bin EapPublished in: Molecular psychiatry (2023)
Patients suffering from mental disorders are at high risk of developing cardiovascular diseases, leading to a reduction in life expectancy. Genetic variants can display greater influence on cardiometabolic features in psychiatric cohorts compared to the general population. The difference is possibly due to an intricate interaction between the mental disorder or the medications used to treat it and metabolic regulations. Previous genome wide association studies (GWAS) on antipsychotic-induced weight gain included a low number of participants and/or were restricted to patients taking one specific antipsychotic. We conducted a GWAS of the evolution of body mass index (BMI) during early (i.e., ≤ 6) months of treatment with psychotropic medications inducing metabolic disturbances (i.e., antipsychotics, mood stabilizers and some antidepressants) in 1135 patients from the PsyMetab cohort. Six highly correlated BMI phenotypes (i.e., BMI change and BMI slope after distinct durations of psychotropic treatment) were considered in the analyses. Our results showed that four novel loci were associated with altered BMI upon treatment at genome-wide significance (p < 5 × 10 -8 ): rs7736552 (near MAN2A1), rs11074029 (in SLCO3A1), rs117496040 (near DEFB1) and rs7647863 (in IQSEC1). Associations between the four loci and alternative BMI-change phenotypes showed consistent effects. Replication analyses in 1622 UK Biobank participants under psychotropic treatment showed a consistent association between rs7736552 and BMI slope (p = 0.017). These findings provide new insights into metabolic side effects induced by psychotropic drugs and underline the need for future studies to replicate these associations in larger cohorts.
Keyphrases
- weight gain
- body mass index
- end stage renal disease
- genome wide
- drug induced
- birth weight
- newly diagnosed
- ejection fraction
- chronic kidney disease
- genome wide association
- cardiovascular disease
- peritoneal dialysis
- mental health
- liver injury
- type diabetes
- prognostic factors
- patient reported outcomes
- dna methylation
- gene expression
- cardiovascular events
- bipolar disorder
- genome wide association study
- patient reported
- cross sectional
- oxidative stress
- preterm birth